Ravi Vij & Dr. Sikander Ailawadhi MD, Discusses ASCO 2025: Subcutaneous Isatuximab At Last!
Автор: MyCancerHaven for Healthcare Professionals
Загружено: 2025-08-25
Просмотров: 15
Ravi Vij & Dr. Sikander Ailawadhi MD, Discusses ASCO 2025: Subcutaneous Isatuximab At Last!
Join Dr. Ravi Vij and Dr. Sikander Ailawadhi as they delve into one of the most anticipated advancements presented at ASCO 2025 — the arrival of subcutaneous isatuximab. In this insightful discussion, they explore the clinical impact, patient convenience, and future implications of this novel delivery method for isatuximab in the treatment of multiple myeloma.
✔️ What does the data show?
✔️ How does subcutaneous isatuximab compare to IV administration?
✔️ What does this mean for patients and oncologists?
Don't miss this expert breakdown of a major milestone in myeloma care.
🔔 Subscribe for more expert insights from ASCO 2025 and beyond!
📌 Leave your questions and thoughts in the comments below.
#ASCO2025 #Isatuximab #MultipleMyeloma #Hematology #Oncology #CancerResearch #DrRaviVij #DrSikanderAilawadhi #SubcutaneousTherapy
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
